See more : K2 Asset Management Holdings Ltd (KAM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Corvus Pharmaceuticals, Inc. (CRVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corvus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Technofab Engineering Limited (TECHNOFAB.NS) Income Statement Analysis – Financial Results
- Venus Medtech (Hangzhou) Inc. (VMTHF) Income Statement Analysis – Financial Results
- Handelsinvest Defensiv 10 Akkumulerende AK (HAID10AKK.CO) Income Statement Analysis – Financial Results
- Manitou Gold Inc. (MTU.V) Income Statement Analysis – Financial Results
- PT Diagnos Laboratorium Utama Tbk (DGNS.JK) Income Statement Analysis – Financial Results
Corvus Pharmaceuticals, Inc. (CRVS)
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 0.00 |
| Gross Profit | -151.00K | -367.00K | -460.00K | -632.00K | -743.00K | -847.00K | -842.00K | -594.00K | -148.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.53M | 24.47M | 29.12M | 31.83M | 37.98M | 38.59M | 46.31M | 29.36M | 11.35M | 41.46K |
| General & Administrative | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
| Other Expenses | 0.00 | 587.00K | 235.00K | 37.46M | 0.00 | 0.00 | 0.00 | 0.00 | -17.60M | 0.00 |
| Operating Expenses | 23.41M | 32.57M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
| Cost & Expenses | 23.41M | 32.57M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
| Interest Income | 0.00 | 654.00 | 0.00 | 540.00K | 2.18M | 2.28M | 861.00K | 601.00K | 35.00K | 0.00 |
| Interest Expense | 1.58M | 654.00K | 15.00K | 540.00K | 2.18M | 2.28M | 0.00 | 601.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 175.64K |
| EBITDA | -26.88M | -40.94M | -42.78M | -5.36M | -48.85M | -46.09M | -54.82M | -35.78M | -31.19M | 14.64K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -23.41M | -32.57M | -38.63M | -43.76M | -48.85M | -49.22M | -56.52M | -36.98M | -13.77M | -175.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.62M | -8.74M | -4.61M | 37.77M | 2.18M | 2.28M | 861.00K | 601.00K | -17.57M | 0.00 |
| Income Before Tax | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 8.74M | -5.04M | -1.17M | -2.93M | 2.28M | -842.00K | -594.00K | -35.00K | 0.00 |
| Net Income | -27.03M | -50.05M | -38.20M | -4.82M | -43.75M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| EPS Diluted | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| Weighted Avg Shares Out | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.00K |
| Weighted Avg Shares Out (Dil) | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.28K |
Down 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
SA Marketplace 2021 Top Idea Contest: Mid-Year Update
Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations
Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
HID Global Civil Registry Solution Advances Antigua and Barbuda’s Transformation to a Digital Society
Source: https://incomestatements.info
Category: Stock Reports